More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Orphan drugs accounted for only 7.9% of total drug sales in the U.S. in 2016, according to a recent QuintilesIMS study, but have accounted for more than 40% of new molecular entity approvals over the past three years. The FDA has recently moved to...

Pfizer announced earlier this month that it is considering strategic alternatives to its consumer healthcare business. So what options may be ahead? The over-the-counter (OTC) drug market has seen several high-profile moves over the past several...

Several contract manufacturers of small-molecule active pharmaceutical ingredients (APIs) and intermediates have recently announced or completed expansions. So which companies are making the moves in the fine-chemicals market? The supply structure...

Specialty pharmaceuticals are projected to account for more than one-third of the global pharmaceutical market by 2021. So what are the drivers behind the growth? The US accounts for more than half of the specialty pharmaceutical market and more...

After showing strong confidence in the overall economic performance and company performance, chief financial officers (CFOs) are tempering their outlook. A recent measure of business confidence shows that concerns over geopolitical risk and talent...

The US Food and Drug Administration (FDA) has approved 33 new molecular entities (NMEs) thus far in 2017, already surpassing the 2016 total of 22. So which drugs are making the mark? Following a downturn in 2016, new drug approvals are on the...

Blockchain is still an emerging technology, but it is gaining increased interest for use in the pharmaceutical supply chain. Blockchain has growing interest across all sectors, including in the pharmaceutical industry. A new pilot program seeks to...

This year thus far has seen several high-profile deals and expansion moves in the contract development and manufacturing sector for drug products. So what moves should be on your radar? There have been several noteworthy moves shaping the...

Earlier this month, Novartis announced that Joseph Jimenez, current CEO , will step down as CEO in February 2018 and turn the reins over to Vasant Narasimhan, MD, current global head of drug development and chief medical officer at Novartis, who...